Our precision medicine team attending ASCO this week share their highlights of a busy day 3 at the conference.
1. The increased use of liquid biopsy assays in surveillance setting, in particular the MRD-based tests, has been a key topic during the ASCO 2023 annual meeting. An ASCO Daily News featured commentary article has further emphasized the importance of the MRD-based test in bringing new treatment opportunities to patients. ctDNA testing has been identified as an integral biomarker to enable more patients to be selected for clinical trials. New therapeutic strategies, including vaccine- and immunotherapy based targeted therapy were also approved for later-line.*
*Source: ASCO Daily News
2. The use of microbiome in cancer care is still at its very early-stage, at Diaceutics we believe the recent advanced research results related to the assay/computational analysis algorithm development to evaluate individual’s dysbiosis status and microbiome directed treatment, (FMT/bacteria based oral drug-CBM588) promise the clinical importance of microbiome as a biomarker in the field of immuno-oncology. However, the microbiome collection needs to be incorporated into more I/O clinical trials to further validate the sensitivity and specificity of the testing assay/algorithm.
*Source: abstract #103 talk “Friendly-user score assessing gut dysbiosis and resistance to immune checkpoint inhibitors (ICI)”; abstract #LBA104 talk “Effect of CBM588 in combination with cabozantinib plus nivolumab for patients (pts) with metastatic renal cell carcinoma (mRCC): A randomized clinical trial”; abstract #105 talk “Fecal microbiota transplantation combined with anti-PD-1 inhibitor for unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor”.
3. Large scale studies show a counter-play interaction between germline genetic alterations and somatic mutational landscapes, which can influence the therapeutic considerations, in particular the combination targeted therapy. Thus, we believe germline sequencing test is equally important to patients with or without high risk of hereditary cancer to ensure accurate diagnosis to direct biomarker driven standard and emerging therapies. Equitable access genetic testing for all is the first step.*
*Source: abstract #10509 talk “Effect of germline mutations on somatic alteration landscapes in BRCA-associated cancers.”, abstract #10510 “Redefining early-onset cancer and risk of hereditary cancer predisposition”, abstract #10511 talk “POT1 germline pathogenic variants and evolving understanding of tumor spectrum: Evidence for lung cancer predisposition”, abstract #11512 talk ” Germline alterations in patients with lung cancer”.
Contact us to discuss how we can support your commercialization goals: Contact Us - Diaceutics
What to know more about MRD testing? Discover our latest report here: https://lp.diaceutics.com/mrd-report-download-form/
